Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers.

Cancers (Basel) · 2021 · PMC8582522 · PMID 34771578

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the IMvigor130 trial, addition of atezolizumab to PBC prolonged PFS; however, improvement in OS did not reach statistical significance at interim analysis [ 77 , 78 , 79 ].

also in 111,027 other papers

a clear trendno p-value reported

One study demonstrated certain organ involvement, thyroid for example, associated with favorable outcomes versus others that did not show a clear trend or were associated with worse prognosis [ 190 , 191 ]. 3.3.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.